Udvalget for Humanmedicinske Lægemidler (CHMP) fandt, at de gavnlige virkninger af OPTISON opvejer risiciene ved diagnosticering af patienter med formodet eller konstateret hjerte- karsygdom.
The Committee for Medicinal products for Human Use (CHMP) decided that OPTISON’ s benefits are greater than its risks to help diagnose patients with suspected or established cardiovascular disease.